Imaging in pleural mesothelioma: A review of the 11th International Conference of the International Mesothelioma Interest Group

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 190-196

  Armato, Samuel G ^a   Labby, Zacariah E ^a   Coolen, Johan ^b   Klabatsa, Astero ^c   Feigen, Malcolm ^d   Persigehl, Thorsten ^e,f   Gill, Ritu R ^g  

^a UNIVERSITY OF CHICAGO   (United States)

^b Department of Radiology ^*  (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d AUSTIN HEALTH   (Australia)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f Columbia University ^*  (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diffusion weighted imaging; Dynamic contrast enhanced CT; Observer variability; PET CT; Prognosis; Radiation therapy; Tumor response assessment; Tumor volume

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE CLASSIFICATION; DISEASE MARKER; GLYCOLYSIS; HEMATOTHORAX; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG VOLUME; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION PNEUMONIA; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

DIFFUSION-WEIGHTED IMAGING; DYNAMIC CONTRAST-ENHANCED CT; OBSERVER VARIABILITY; PET/CT; PROGNOSIS; RADIATION THERAPY; TUMOR RESPONSE ASSESSMENT; TUMOR VOLUME;

DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LUNG NEOPLASMS; LUNG VOLUME MEASUREMENTS; MESOTHELIOMA; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84887014715     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.005     Document Type: Review

References (30)

1. Suzuki Y. Pathology of human malignant mesothelioma - preliminary analysis of 1517 mesothelioma cases. Ind Health 2001, 39:183-185.
2. Corson N., Sensakovic W.F., Straus C., Starkey A., Armato S.G. Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans. Med Phys 2011, 38:942-947.
3. Gill R.R., Gerbaudo V.H., Jacobson F.L., Trotman-Dickenson B., Matsuoka S., Hunsaker A., et al. MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin N Am 2008, 16:319-339.
4. Gill R.R., Umeoka S., Mamata H., Tilleman T.R., Stanwell P., Woodhams R., et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR 2010, 195:W125-W130.
5. Francis R.J., Byrne M.J., van der Schaaf A.A., Boucek J.A., Nowak A.K., Phillips M., et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007, 48:1449-1458.
6. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
7. Armato S.G., Oxnard G.R., MacMahon H., Vogelzang N.J., Kindler H.L., Kocherginsky M., et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 2004, 31:1105-1115.
8. Labby Z.E., Armato S.G., Kindler H.L., Dignam J.J., Hasani A., Nowak A.K. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol 2012, 7:1728-1734.
9. Oxnard G.R., Armato S.G., Kindler H.L. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 2006, 52:141-148.
10. Liu F., Zhao B., Krug L.M., Ishill N.M., Lim R.C., Guo P., et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol 2010, 5:879-884.
11. Frauenfelder T., Tutic M., Weder W., Gotti R.P., Stahel R.A., Seifert B., et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma. Eur Respir J 2011, 38:162-168.
12. Sensakovic W.F., Armato S.G., Straus C., Roberts R.Y., Caligiuri P., Starkey A., et al. Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys 2011, 38:238-244.
13. Gill R.R., Richards W.G., Yeap B.Y., Matsuoka S., Wolf A.S., Gerbaudo V.H., et al. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR 2012, 198:359-363.
14. Labby Z.E., Nowak A.K., Dignam J.J., Straus C., Kindler H.L., Armato S.G. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol 2013, 24:999-1005.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
16. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
17. Armato S.G., Ogarek J.L., Starkey A., Vogelzang N.J., Kindler H.L., Kocherginsky M., et al. Variability in mesothelioma tumor response classification. AJR 2006, 186:1000-1006.
18. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
19. Sensakovic W.F., Armato S.G., Starkey A., Kindler H.L., Vigneswaran W.T. Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol 2011, 18:294-298.
20. Mehrara E., Forssell-Aronsson E., Bernhardt P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br J Cancer 2011, 105:682-686.
21. Labby Z.E., Armato S.G., Dignam J.J., Straus C., Kindler H.L., Nowak A.K. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol 2013, 8:478-486.
22. Avants B.B., Tustison N.J., Song G., Cook P.A., Klein A., Gee J.C. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011, 54:2033-2044.
23. Miles K.A. Perfusion CT for the assessment of tumour vascularity: which protocol?. Brit J Radiol 2003, 76. Spec No 1:S36-42.
24. Miles K.A., Griffiths M.R. Perfusion CT: a worthwhile enhancement?. Brit J Radiol 2003, 76:220-231.
25. Coolen J., De Keyzer F., Nafteux P., De Wever W., Dooms C., Vansteenkiste J., et al. Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging - initial experience. Radiology 2012, 263:884-892.
26. Kawashima A., Libshitz H.I. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR 1990, 155:965-969.
27. Scire C.A., Caporali R., Zanierato M., Mojoli F., Braschi A., Montecucco C. Shrinking lung syndrome in systemic sclerosis. Arthritis Rheum 2003, 48:2999-3000.
28. Chung-Park M., Tomashefski J.F., Cohen A.M., el-Gazzar M., Cotes E.E. Shrinking pleuritis with lobar atelectasis, a morphologic variant of round atelectasis. Hum Pathol 1989, 20:382-387.
29. Singh R., Huang W., Menon Y., Espinoza L.R. Shrinking lung syndrome in systemic lupus erythematosus and Sjogren's syndrome. J Clin Rheumatol 2002, 8:340-345.
30. Rimner A., Rosenzweig K.E. Novel radiation therapy approaches in malignant pleural mesothelioma. Ann Cardiothorac Surg 2012, 1:457-461.